vancomycin TDM

vancomycin TDM estimates individualized vancomycin pharmacokinetics and supports therapeutic drug monitoring using a population pharmacokinetic model developed from data on 220 Korean patients.

Key Features:

• Population pharmacokinetic model: A two-compartment model with first-order elimination describing vancomycin pharmacokinetics in the Korean population.
• Modeling approach: Developed using non-linear mixed effects (NLME) modeling to provide population and individual parameter estimates.
• Parameter estimates: Reported population PK parameters include clearance (CL) 2.82 L/h, central volume (V1) 31.8 L, inter-compartmental transfer rate (Q) 11.7 L/h, and peripheral volume (V2) 75.4 L.
• Covariate integration: Covariate analysis incorporates body weight (affecting V2), creatinine clearance, and renal replacement modalities including hemodialysis and continuous renal replacement therapy (CRRT) affecting vancomycin clearance.
• Development dataset: Model calibrated on TDM data from 220 Korean patients who received vancomycin.
• Implementation: Final model implemented in R Shiny.

Scientific Applications:

• Personalized dosing: Inform individualized vancomycin dosing regimens and therapeutic drug monitoring for Korean patients.
• Renal impairment and RRT management: Support dosing adjustments for patients with impaired renal function and those undergoing hemodialysis or CRRT.
• Population-specific refinement: Address pharmacokinetic variability specific to the Korean population compared to models derived from Western populations.

Methodology:

Model development used non-linear mixed effects modeling of a two-compartment model with first-order elimination, including covariate analysis for body weight, creatinine clearance, hemodialysis, and CRRT; the final model was implemented in R Shiny.